Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

IRVING, Texas--(BUSINESS WIRE)--InspiroGene™ by McKesson today announced the publication of its inaugural 2024 Cell and Gene Therapy Report: Advancing the Future of Medicine.

InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges

Adobe

Green Plains

Super Micro Computer

Zscaler

24/7 Wall St. Insights Selecting stocks for the long haul can be a challenge.

Prediction: This Will Be the Best-Performing Stock in 2030

McKesson (MCK) reachead $488.78 at the closing of the latest trading day, reflecting a -1.95% change compared to its last close.

McKesson (MCK) Stock Dips While Market Gains: Key Facts

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why McKesson (MCK) is a Strong Value Stock

Lam Research

While dividend stock investing is one of the best strategies an investor can pursue to create phenomenal wealth, chasing yield can undermine the entire effort.

You Should Be Investing in Dividend Growth Stocks. These Are the 2 Best to Buy In October

IRVING, Texas--(BUSINESS WIRE)--McKesson launches InspiroGene by McKesson, a dedicated business focused solely on supporting the commercialization of cell and gene therapies.

McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies

The latest trading day saw McKesson (MCK) settling at $479.06, representing a -0.02% change from its previous close.

McKesson (MCK) Stock Sinks As Market Gains: Here's Why

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?

The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often experience a rally.

Stock Of The Day: Has McKesson Found Its Bottom And Will It Bounce Back?

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide pr.

McKesson Corporation Announces Second Quarter Fiscal 2025 Earnings Release Date

Becton, Dickinson and Co.

Cooper Companies

STAAR Surgical

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.

4 Stocks to Buy Amid Dental Supplies Industry Challenges

In the latest trading session, McKesson (MCK) closed at $508.16, marking a -0.68% move from the previous day.

McKesson (MCK) Stock Slides as Market Rises: Facts to Know Before You Trade

MCK's strategic collaborations and strength in Biologics raise optimism about the stock.

Here's Why You Should Retain McKesson Stock in Your Portfolio Now

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why McKesson (MCK) is a Top Value Stock for the Long-Term

McKesson's recent sell-off offers a compelling opportunity, driven by its strong position in healthcare distribution and growing focus on AI and technology for sustainable growth. The company boasts solid revenue and EPS growth, supported by AI integration, expansion into high-demand sectors like GLP-1 and oncology, and a robust business model. Shareholder returns are enhanced by aggressive buyback plans, a 15% dividend hike, and a healthy balance sheet, despite a low 0.6% dividend yield.

McKesson - Meet The New Dividend Stock On My Watchlist

McKesson (MCK) reachead $518.81 at the closing of the latest trading day, reflecting a +1.49% change compared to its last close.

McKesson (MCK) Exceeds Market Returns: Some Facts to Consider

McKesson (MCK) concluded the recent trading session at $511.17, signifying a +0.14% move from its prior day's close.

McKesson (MCK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

News Corp

The Nasdaq 100 closed lower by over 500 points during Friday's session. Investors, meanwhile, focused on some notable insider trades.

McKesson, News Corporation And 2 Other Stocks Executives Are Selling

Alithya Group Inc

ALPHARETTA, Ga. , Sept. 9, 2024 /PRNewswire/ - Alithya Group inc.

Alithya to co-present with McKesson at Oracle CloudWorld 2024

MCK announces the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, aligning with its strategy to grow oncology and biopharma services.

McKesson Shares Fall Following Sale of Rexall, Well.ca to Birch Hill

Major U.S. equities indexes were mixed as the latest ADP jobs data showed a smaller-than-expected jump in private payrolls in August.

S&P 500 Gains and Losses Today: McKesson Falls Amid Plans To Exit Canada Businesses

Drug distributor McKesson on Thursday forecast second-quarter profit below Wall Street estimates.

Drug distributor McKesson forecasts Q2 profit below estimates

McKesson Corporation (NYSE:MCK ) Wells Fargo 2024 Healthcare Conference September 5, 2024 8:45 AM ET Company Participants Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Stephen Baxter - Wells Fargo Stephen Baxter Good morning. I'm Steve Baxter, the Healthcare Services Analyst at Wells Fargo.

McKesson Corporation (MCK) Wells Fargo 2024 Healthcare Conference (Transcript)

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. In line with McKesson Corporation's enterprise strategy, this transaction enables McKesson to further focus and prioritize investments to grow its oncology and biopharma services platforms. McKesson Corporation remains fully committed to and confident in the strength.

News for McKesson Stock (MCK)